Pharmacotherapy of yeast infections

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 16, 2008, Pages 2801-2816

  Gómez López, Alicia ^a   Zaragoza, Oscar ^a   Rodríguez Tudela, Juan Luis ^a   Cuenca Estrella, Manuel ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Amphotericin B; Azole; Candida spp.; Cryptococcus neoformans; Echinocandins; Pathogenic yeast; Pharmacotherapy

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; CASPOFUNGIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; NYSTATIN; POSACONAZOLE; VORICONAZOLE;

ANTIBIOTIC PROPHYLAXIS; ANTIFUNGAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; CANDIDA ENDOCARDITIS; CANDIDA ENDOPHTHALMITIS; CANDIDA MENINGITIS; CANDIDEMIA; CANDIDIASIS; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCUS; CRYPTOCOCCUS GATTII; CRYPTOCOCCUS NEOFORMANS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG MEGADOSE; ESOPHAGUS CANDIDIASIS; FUNGAL STRAIN; HUMAN; INFECTION SENSITIVITY; INJECTION SITE REACTION; MAINTENANCE THERAPY; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; NEPHROTOXICITY; NONHUMAN; OROPHARYNX CANDIDIASIS; REVIEW; RHODOTORULA; URINARY TRACT INFECTION; VAGINA CANDIDIASIS;

ANIMALS; ANTIFUNGAL AGENTS; CANDIDIASIS; DISEASE SUSCEPTIBILITY; HUMANS; UROLOGIC DISEASES;

EID: 56749091426     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.16.2801     Document Type: Review

References (145)

1. Rex JH, Alexander BA, Andes D, et al. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard. 3rd edition. CLSI Document M27-A3. 2008. Wayne, PA, USA: Clinical and Laboratory Standards Institute
2. Subcommittee on Antifungal Susceptibility Testing of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST): EUCAST definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeast. Clin Microbiol Infect 2008;14:398-405
3. Phillips AJ, Sudbery I, Ramsdale M. Apoptosis induced by environmental stresses and amphotericin B in Candida albicans. Proc Natl Acad Sci USA 2003;100:14327-32
4. Aramwit P, Yu BG, Lavasanifar A, et al. The effect of serum albumin on the aggregation state and toxicity of amphotericin B. J Pharm Sci 2000;89:1589-93
5. Dupont B. Overview of the lipid formulations of amphotericin B. J Antimicrob Chemother 2002;49(Suppl 1):31-6
6. Cuenca-Estrella M, Gomez-Lopez A, Mellado E, et al. Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi. Antimicrob Agents Chemother 2006;50:917-21
7. Pappas PG, Rex JH, Sobel JD, et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004;38:161-89
8. Alonso-Vargas R, Gonzalez-Alvarez L, Ruesga MT, et al. In vitro activity of a liposomal nystatin formulation (Nyotran) against Cryptococcus neoformans. Rev Iberoam Micol 2000;17:90-2
9. Arikan S, Rex JH. Nystatin LF (Aronex/Abbott). Curr Opin Invest Drugs 2001;2:488-95
10. Cuenca-Estrella M, Rodriguez D, Almirante B, et al. In vitro susceptibilities of bloodstream isolates of Canditda species to six antifungal agents: results from a population-based active surveillance programme, Barcelona, Spain, 2002-2003. J Antimicrob Chemother 2005;s:194-9
11. Ally R, Schurmann D, Kreisel W, et al. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis 2001;33:1447-54
12. Nagappan V, Deresinski S. Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent. Clin Infect Dis 2007;45:1610-7
13. Boucher HW, Groll AH, Chiou CC, Walsh TJ. Newer systemic antifungal agents: pharmacokinetics, safety and efficacy. Drugs 2004;64:1997-2020
14. Denning DW. Echinocandin antifungal drugs. Lancet 2003;362:1142-51
15. Vermes A, Guchelaar HJ, Dankert J. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J Antimicrob Chemother 2000;46:171-9
16. Asmundsdottir LR, Erlendsdottir H, Gottfredsson M. Increasing incidence of candidemia: results from a 20-year nationwide study in Iceland. J Clin Microbiol 2002;40:3489-92
17. Edmond MB, Wallace SE, McClish DK, et al. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis 1999;29:239-44
18. Pfaller MA, Diekema DJ, Jones RN, et al. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY Antimicrobial Surveillance Program. J Clin Microbiol 2001;39:3254-9
19. Pfaller MA, Jones RN, Messer SA, et al. National surveillance of nosocomial blood stream infection due to Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. Diagn Microbiol Infect Dis 1998;31:327-32
20. Macphail GL, Taylor GD, Buchanan-Chell M, et al. Epidemiology, treatment and outcome of candidemia: a five-year review at three Canadian hospitals. Mycoses 2002;45:141-5
21. Baran J Jr, Muckatira B, Khatib R. Candidemia before and during the fluconazole era: prevalence, type of species and approach to treatment in a tertiary care community hospital. Scand J Infect Dis 2001;33:137-9
22. Diekema DJ, Messer SA, Brueggemann AB, et al. Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study. J Clin Microbiol 2002;40:1298-302
23. Trick WE, Fridkin SK, Edwards JR, et al. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis 2002;35:627-30
24. Hope W, Morton A, Eisen DP. Increase in prevalence of nosocomial non-Candida albicans candidaemia and the association of Candida krusei with fluconazole use. J Hosp Infect 2002;50:56-65
25. Hachem R, Hanna H, Kontoyiannis D, et al. The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy. Cancer 2008;112:2493-9
26. Richardson M, Lass-Florl C. Changing epidemiology of systemic flungal infections. Clin Microbiol Infect 2008;14(Suppl 4):5-24
27. Alcoba-Florez J, Mendez-Alvarez S, Cano J, et al. Phenotypic and molecular characterization of Candida nivariensis sp. nov., a possible new opportunistic fungus. J Clin Microbiol 2005;43:4107-11
28. Correia A, Sampaio P, James S, Pais C. Candida bracarensis sp. nov., a novel anamorphic yeast species phenotypically similar to Candida glabrata. Int J Syst Evol Microbiol 2006;56:313-7
29. Sullivan DJ, Westerneng TJ, Haynes KA, et al. Candida dubliniensis sp. nov.: phenotypic and molecular characterization of a novel species associated with oral candidosis in HIV-infected individuals. Microbiology 1995;141(Part 7):1507-21
30. Tavanti A, Davidson AD, Gow NA, et al. Candida orthopsilosis and Candida metapsilosis spp. nov. to replace Candida parapsilosis groups II and III. J Clin Microbiol 2005;43:284-92
31. Gomez-Lopez A, Alastruey-Izquierdo A, Rodriguez D, et al. Prevalence and susceptibility profile of Candida metapsilosis and Candida orthopsilosis: results from population-based surveillance of candidemia in Spain. Antimicrob Agents Chemother 2008;52:1506-9
32. Pfaller MA, Messer SA, Boyken L, et al. Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002. J Clin Microbiol 2004;42:3142-6
33. Pfaller MA, Diekema DJ, Rinaldi MG, et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing. J Clin Microbiol 2005;43:5848-59
34. Kabbara N, Lacroix C, De Latour RP, et al. Breakthrough C. parapsilosis and C. guilliermondii blood stream infections in allogeneic hematopoietic stem cell transplant recipients receiving long-term caspofungin therapy. Haematologica 2008;93:639-40
35. Garcia-Effron G, Katiyar SK, Park S, et al. A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. Antimicrob Agents Chemother 2008;52:2305-12
36. Forrest GN, Weekes E, Johnson JK. Increasing incidence of Candida parapsilosis candidemia with caspofungin usage. J Infect 2008;56:126-9
37. Dimopoulos G, Ntziora F, Rachiotis G, et al. Candida albicans versus non-albicans intensive care unit-acquired bloodstream infections: differences in risk factors and outcome. Anesth Analg 2008;106:523-9
38. Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002;347:2020-9
39. Glockner A, Cornely OA. Echinocandins in invasive candidiasis. Med Klin (Munich) 2008;103:397-405
40. Kuse ER, Chetchotisakd P, Da Cunha CA, et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007;369:1519-27
41. Reboli AC, Rotstein C, Pappas PG, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007;356:2472-82
42. Pappas PG, Rotstein CM, Betts RF, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007;45:883-93
43. Kullberg BJ, Sobel JD, Ruhnke M, et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 2005;366:1435-42
44. Scott LJ, Simpson D. Voriconazole: a review of its use in the management of invasive fungal infections. Drugs 2007;67:269-98
45. Pan SC, Hsieh SM, Chang SC, et al. Septic Candida krusei thrombophlebitis of inferior vena cava with persistent fungemia successfully treated by new antifungal agents. Med Mycol 2005;43:731-4
46. Schilling A, Seibold M, Mansmann V, Gleissner B. Successfully treated Candida krusei infection of the lumbar spine with combined caspofungin/ posaconazole therapy. Med Mycol 2008;46:79-83
47. Baddley JW, Pappas PG. Antifungal combination therapy: clinical potential. Drugs 2005;65:1461-80
48. Johnson MD, MacDougall C, Ostrosky-Zeichner L, et al. Combination antifungal therapy. Antimicrob Agents Chemother 2004;48:693-715
49. Spreghini E, Maida CM, Milici ME, et al. Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B. Antimicrob Agents Chemother 2008;52:513-7
50. Barchiesi F, Spreghini E, Fothergill AW, et al. Caspofungin in combination with amphotericin B against Candida glabrata. Antimicrob Agents Chemother 2005;49:2546-9
51. Barchiesi F, Spreghini E, Tomassetti S, et al. Caspofungin in combination with amphotericin B against Candida parapsilosis. Antimicrob Agents Chemother 2007;51:941-5
52. Marine M, Serena C, Pastor FJ, Guarro J. Combined antifungal therapy in a murine infection by Candida glabrata. J Antimicrob Chemother 2006;58:1295-8
53. Olson JA, Adler-Moore JP, Smith PJ, Proffitt RT. Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin. Antimicrob Agents Chemother 2005;49:4895-902
54. Cuenca-Estrella M. Combinations of antifungal agents in therapy - what value are they? J Antimicrob Chemother 2004;54:854-69
55. Rex JH, Pappas PG, Karchmer AW, et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis 2003;36:1221-8
56. Pachl J, Svoboda P, Jacobs F, et al. A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis. Clin Infect Dis 2006;42:1404-13
57. Schaberg DR, Culver DH, Gaynes RP. Major trends in the microbial etiology of nosocomial infection. Am J Med 1991;91:S72-5
58. Kauffman CA, Vazquez JA, Sobel JD, et al. Prospective multicenter surveillance study of funguria in hospitalized patients. The National Institute for Allergy and Infectious Diseases (NIAID) Mycoses Study Group. Clin Infect Dis 2000;30:14-8
59. Malani AN, Kauffman CA. Candida urinary tract infections: treatment options. Expert Rev Antiinfect Ther 2007;5:277-84
60. Sobel JD, Bradshaw SK, Lipka CJ, Kartsonis NA. Caspofungin in the treatment of symptomatic candiduria. Clin Infect Dis 2007;44:e46-9
61. Talarmin JP, Boutoille D, Tattevin P, et al. Candida endocarditis: role of new antifungal agents. Mycoses 2008 May 21
62. Baddley JW, Benjamin DK Jr, Patel M, et al. Candida infective endocarditis. Eur J Clin Microbiol Infect Dis 2008;27:519-29
63. Hope WW, Mickiene D, Petraitis V, et al. The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates. J Infect Dis 2008;197:163-71
64. Silverman S Jr, Luangjarmekorn L, Greenspan D. Occurrence of oral Candida in irradiated head and neck cancer patients. J Oral Med 1984;39:194-6
65. Sobel JD, Brooker D, Stein GE, et al. Single oral dose fluconazole compared with conventional clotrimazole topical therapy of Candida vaginitis. Fluconazole Vaginitis Study Group. Am J Obstet Gynecol 1995;172:1263-8
66. Vazquez JA, Hidalgo JA, De Bono S. Use of sargramostim (rh-GM-CSF) as adjunctive treatment of fluconazole-refractory oropharyngeal candidiasis in patients with AIDS: a pilot study. HIV Clin Trials 2000;1:23-9
67. Coleman DC, Bennett DE, Sullivan DJ, et al. Oral Candida in HIV infection and AIDS: new perspectives/new approaches. Crit Rev Microbiol 1993;19:61-82
68. Vazquez JA, Skiest DJ, Nieto L, et al. A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of otopharyngeal candidiasis in subjects with HIV/AIDS. Clin Infect Dis 2006;42:1179-86
69. Sobel JD. Vaginitis. N Engl J Med 1997;337:1896-903
70. Sobel JD, Wiesenfeld HC, Martens M, et al. Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. N Engl J Med 2004;351:876-83
71. Casadevall A, Perfect JR, editors, Cryptococcus neoformans. Washington: ASM Press; 1998
72. Vecchiarelli A. Fungal capsular polysaccharide and T-cell suppression: the hidden nature of poor immunogenicity. Crit Rev Immunol 2007;27:547-57
73. Larsen RA, Bauer M, Brouwer AE, et al. In vitro-Clinical correlations for amphotericin B susceptibility in AIDS-associated cryptococcal meningitis. Antimicrob Agents Chemother 2007;51:343-5
74. Brandt ME, Pfaller MA, Hajjeh PA, et al. Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates in the United States: 1992 to 1994 and 1996 to 1998. Antimicrob Agents Chemother 2001;45:3065-9
75. Perkins A, Gomez-Lopez A, Mellado E, et al. Rates of antifungal resistance among Spanish clinical isolates of Cryptococcus neoformans var. neoformans. J Antimicrob Chemother 2005;56:1144-7
76. Franzot SP, Hamdan JS. In vitro susceptibilities of clinical and environmental isolates of Cryptococcus neoformans to five antifungal drugs. Antimicrob Agents Chemother 1996;40:822-4
77. Pfaller MA, Messer SA, Boyken L, et al. In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS Global Antifungal Surveillance Program. Diagn Microbiol Infect Dis 2004;48:201-5
78. Yildiran ST, Fothergill AW, Sutton DA, Rinaldi MG. In vitro susceptibilities of cerebrospinal fluid isolates of Cryptococcus neoformans collected during a ten-year period against fluconazole, voriconazole and posaconazole (SCH56592). Mycoses 2002;45:378-83
79. Pfaller MA, Messer SA, Hollis RJ, Jones RN. In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans. Antimicrob Agents Chemother 2001;45:2862-4
80. Nguyen MH, Yu CY. In vitro comparative efficacy of voriconazole and itraconazole against fluconazole-susceptible and -resistant Cryptococcus neoformans isolates. Antimicrob Agents Chemother 1998;42:471-2
81. Brummer E, Kamei K, Miyaji M. Anticryptococcal activity of voriconazole against Cryptococcus neoformans var. gatti vs var. neoformans: comparison with fluconazole and effect of human serum. Mycopathologia 1998;142:3-7
82. Pfaller MA, Messer SA, Boyken L, et al. In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS Global Antifungal Surveillance Program. Diagn Microbiol Infect Dis 2004;48:201-5
83. Brummer E, Kamei K, Miyaji M. Damage to yeast cells of Cryptococcus neoformans by voriconazole and fluconazole: a culture and microscopic study. Med Mycol 1998;36:227-33
84. Van Duin D, Cleare W, Zaragoza O, et al. Effects of voriconazole on Cryptococcus neoformans. Antimicrob Agents Chemother 2004;48:2014-20
85. Martinez LR, Ntiamoah P, Gacser A, et al. Voriconazole inhibits melanization in Cryptococcus neoformans. Antimicrob Agents Chemother 2007;51:4396-400
86. Illnait-Zaragozi MT, Martinez GF, Curfs-Breuker I, et al. In vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba. Antimicrob Agents Chemother 2008;52:1580-2
87. Yamazumi T, Pfaller MA, Messer SA, et al. In vitro activities of ravuconazole (BMS-207147) against 541 clinical isolates of Cryptococcus neoformans. Antimicrob Agents Chemother 2000;44:2883-6
88. Cuenca-Estrella M, Gomez-Lopez A, Mellado E, et al. In vitro activities of ravuconazole and four other antifungal agents against fluconazole-resistant or -susceptible clinical yeast isolates. Antimicrob Agents Chemother 2004;48:3107-11
89. Bicanic T, Harrison T, Niepieklo A, et al. Symptomatic relapse of HIV-associated cryptococcal meningitis after initial fluconazole monotherapy: the role of fluconazole resistance and immune reconstitution. Clin Infect Dis 2006;43:1069-73
90. Hsueh PR, Lau YJ, Chuang YC, et al. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003. Antimicrob Agents Chemother 2005;49:512-7
91. Sar B, Monchy D, Vann M, et al. Increasing in vitro resistance to fluconazole in Cryptococcus neoformans Cambodian isolates: April 2000 to March 2002. J Antimicrob Chemother 2004;54:563-5
92. Saag MS, Graybill RJ, Larsen RA, et al. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis 2000;30:710-8
93. De Wytt CN, Dickson PL, Holt GW. Cryptococcal meningitis. A review of 32 years experience. J Neurol Sci 1982;53:283-92
94. Sahai J. Management of cryptococcal meningitis in patients with AIDS. Clin Pharm 1988;7:528-35
95. Shadomy S, Wagner G, Espinel-Ingroff E, Davis BA. In vitro studies with combinations of 5-fluorocytosine and amphotericin B. Antimicrob Agents Chemother 1975;8:117-21
96. Polak A, Scholer HJ, Wall M. Combination therapy of experimental candidiasis, cryptococcosis and aspergillosis in mice. Chemotherapy 1982;28:461-79
97. Nguyen MH, Najvar LK, Yu CY, Graybill JR. Combination therapy with fluconazole and flucytosine in the murine model of cryptococcal meningtis. Antimicrob Agents Chemother 1997;41:1120-3
98. Van Der Horst CM, Saag MS, Cloud GA, et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med 1997;337:15-21
99. Bicanic T, Wood R, Meintjes G, et al. High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial. Clin Infect Dis 2008;47:123-30
100. Leenders AC, Reiss P, Portegies P, et al. Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis. AIDS 1997;11:1463-71
101. Sugar AM, Saunders C. Oral fluconazole as suppressive therapy of disseminated cryptococcosis in patients with acquired immunodeficiency syndrome. Am J Med 1988;85:481-9
102. Bozzette SA, Larsen RA, Chiu J, et al. A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. California Collaborative Treatment Group. N Engl J Med 1991;324:580-4
103. Pinner RW, Hajjeh RA, Powderly WG. Prospects for preventing cryptococcosis in persons infected with human immunodeficiency virus. Clin Infect Dis 1995;21(Suppl 1):S103-7
104. Chetchotisakd P, Sungkanuparph S, Thinkhamrop B, et al. A multicentre, randomized, double-blind, placebo-controlled trial of primary cryptococcal meningitis prophylaxis in HIV-infected patients with severe immune deficiency. HIV Med 2004;5:140-3
105. Powderly WG, Saag MS, Cloud GA, et al. A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. The NIAID AIDS Clinical Trials Group and Mycoses Study Group. N Engl J Med 1992;326:793-8
106. Milefchik E, Leal MA, Haubrich R, et al. Fluconazole alone or combined with flucytosine for the treatment of AIDS-associated cryptococcal meningitis. Med Mycol 2008;46:393-5
107. Larsen RA, Bozzette SA, Jones BE, et al. Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1994;19:741-5
108. Larsen RA, Leal MA, Chan LS. Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS. A randomized trial. Ann Intern Med 1990;113:183-7
109. Brouwer AE, Rajanuwong A, Chierakul W, et al. Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet 2004;363:1764-7
110. De Gans J, Portegies P, Tiessens G, et al. Itraconazole compared with amphotericin B plus flucytosine in AIDS patients with cryptococcal meningitis. AIDS 1992;6:185-90
111. Mootsikapun P, Chetchotisakd P, Anunnatsiri S, Choksawadphinyo K. The efficacy of fluconazole 600 mg/day versus itraconazole 600 mg/day as consolidation therapy of cryptococcal meningitis in AIDS patients. J Med Assoc Thai 2003;86:293-8
112. Saag MS, Cloud GA, Graybill JR, et al. A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis 1999;28:291-6
113. Barchiesi F, Spreghini E, Schimizzi AM, et al. Posaconazole and amphotericin B combination therapy against Cryptococcus neoformans infection. Antimicrob Agents Chemother 2004;48:3312-6
114. Barchiesi F, Schimizzi AM, Caselli F, et al. Activity of the new antifungal triazole, posaconazole, against Cryptococcus neoformans. J Antimicrob Chemother 2001;48:769-73
115. Pitisuttithum P, Negroni R, Graybill JR, et al. Activity of posaconazole in the treatment of central nervous system fungal infections. J Antimicrob Chemother 2005;56:745-55
116. Mavrogiorgos N, Zaragoza O, Casadevall A, Nosanchuk JD. Efficacy of voriconazole in experimental Cryptococcus neoformans infection. Mycopathologia 2006;162:111-4
117. Serena C, Pastor FJ, Marine M, et al. Efficacy of voriconazole in a murine model of cryptococcal central nervous system infection. J Antimicrob Chemother 2007;60:162-5
118. Kirkpatrick WR, Najvar LK, Bocanegra R, et al. New guinea pig model of cryptococcal meningitis. Antimicrob Agents Chemother 2007;51:3011-3
119. Martinez LR, Casadevall A. Susceptibility of Cryptococcus neoformans biofilms to antifungal agents in vitro Antimicrob Agents Chemother 2006;50:1021-33
120. Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003;36:1122-31
121. Sabbatani S, Manfredi R, Pavoni M, et al. Voriconazole proves effective in long-term treatment of a cerebral cryptococcoma in a chronic nephropathic HIV-negative patient, after fluconazole failure. Mycopathologia 2004;158:165-71
122. Chen J, Varma A, Diaz MR, et al. Cryptococcus neoformans strains and infection in apparently immunocompetent patients, China. Emerg Infect Dis 2008;14:755-62
123. Fraser JA, Giles SS, Wenink EC, et al. Same-sex mating and the origin of the Vancouver Island Cryptococcus gattii outbreak. Nature 2005;437:1360-4
124. Hoang LM, Maguire JA, Doyle P, et al. Cryptococcus neoformans infections at Vancouver Hospital and Health Sciences Centre (1997-2002): epidemiology, microbiology and histopathology. J Med Microbiol 2004;53:935-40
125. Kidd SE, Hagen F, Tscharke RL, et al. A rare genotype of Cryptococcus gattii caused the cryptococcosis outbreak on Vancouver Island (British Columbia, Canada). Proc Natl Acad Sci USA 2004;101:17258-63
126. Bartlett KH, Kidd SE, Kronstad JW. The emergence of Cryptococcus gattii in British Columbia and the Pacific Northwest. Curr Infect Dis Rep 2008;10:58-65
127. Gomez-Lopez A, Zaragoza O, Dos Anjos MM, et al. In vitro susceptibility of Cryptococcus gattii clinical isolates. Clin Microbiol Infect 2008;14:727-30
128. Rodriguez-Tudela JL, Diaz-Guerra TM, Mellado E, et al. Susceptibility patterns and molecular identification of Trichosporon species. Antimicrob Agents Chemother 2005;49:4026-34
129. Arikan S, Hascelik G. Comparison of NCCLS microdilution method and Etest in antifungal susceptibility testing of clinical Trichosporon asahii isolates. Diagn Microbiol Infect Dis 2002;43:107-11
130. Paphitou NI, Ostrosky-Zeichner L, Paetznick VL, et al. In vitro antifungal susceptibilities of Trichosporon species. Antimicrob Agents Chemother 2002;46:1144-6
131. Gomez-Lopez A, Mellado E, Rodriguez-Tudela JL, Cuenca-Estrella M. Susceptibility profile of 29 clinical isolates of Rhodotorula spp. and literature review. J Antimicrob Chemother 2005;55:312-6
132. Diekema DJ, Petroelje B, Messer SA, et al. Activities of available and investigational antifungal agents against Rhodotorula species. J Clin Microbiol 2005;43:476-8
133. Matsue K, Uryu H, Koseki M, et al. Breakthrough trichosporonosis in patients with hematologic malignancies receiving micafungin. Clin Infect Dis 2006;42:753-7
134. Kucukates E, Erturan Z, Susever S, Yegenoglu Y. In vitro susceptibility of yeasts isolated from patients in intensive care units to fluconazole and amphotericin B during a 3-year period. APMIS 2005;113:278-83
135. Venditti M, Posteraro B, Morace G, Martino P. In vitro comparative activity of fluconazole and other antifungal agents against Blastoschizomyces capitatus. J Chemother 1991;3:13-5
136. Fianchi L, Montini L, Caira M, et al. Combined voriconazole plus caspofungin therapy for the treatment of probable Geotrichum pneumonia in a leukemia patient. Infection 2008;36:65-7
137. Etienne A, Datry A, Gaspar N, et al. Successful treatment of disseminated Geotrichum capitatum infection with a combination of caspofungin and voriconazole in an immunocompromised patient. Mycoses 2008;51:270-2
138. Skovgaard N. New trends in emerging pathogens. Int J Food Microbiol 2007;120:217-24
139. Munoz P, Bouza E, Cuenca-Estrella M, et al. Saccharomyces cerevisiae fungemia: an emerging infectious disease. Clin Infect Dis 2005;40:1625-34
140. De Llanos R, Quetol A, Peman J, et al. Food and probiotic strains from the Saccharomyces cerevisiae species as a possible origin of human systemic infections. Int J Food Microbiol 2006;110:286-90
141. Zerva L, Hollis RJ, Pfaller MA. In vitro susceptibility testing and DNA typing of Saccharomyces cerevisiae clinical isolates. J Clin Microbiol 1996;34:3031-4
142. Milici ME, Maida CM, Spreghini E, et al. Comparison between disk diffusion and microdilution methods for determining susceptibility of clinical fungal isolates to caspofungin. J Clin Microbiol 2007;45:3529-33
143. Morgan J, Meltzer MI, Plikaytis BD, et al. Excess mortality, hospital stay, and cost due to candidemia: a case-control study using data from population-based candidemia surveillance. Infect Control Hosp Epidemiol 2005;26:540-7
144. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005;49:3640-5
145. Parkins MD, Sabuda DM, Elsayed S, Laupland KB. Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections. J Antimicrob Chemother 2007;60:613-8